Check out Chun-Pu's EMBO paper on a new regulator of tumor susceptibility to T cell killing - congrats with this successful completion of very hard work Chun-Pu! embopress.org/doi/10.15252/e…

Congrats to Sebastiaan on his first PhD paper on a new regulator of AXL aacrjournals.org/mcr/article-ab…

Congrats to Disha for publishing her work on how an acidic tumor microenvironment induces immune-suppressive regulatory T cells onlinelibrary.wiley.com/doi/10.1002/ej…

Congrats to Esmee for her paper on apoptosis proteins (IAP) antagonist, cell proliferation and DC cross-presentation aacrjournals.org/cancerimmunolr…

Researchers from Daniel Peeper's NKI research group discovered an unexpected effect of epacadostat, a new type of immunotherapy that inhibits the IDO1 protein. This may explain why this therapy proved ineffective in the final phase of clinical research ➡️ bit.ly/3ZcXrge

Several exciting vacancies (incl. European Research Council (ERC) Adv. grant) in my lab at the The Netherlands Cancer Institute for ambitious postdocs with expertise in immunology and an interest in translational cancer research. More info and applications: nki.nl/research/resea… #postdocjobs #immunotherapy

Person can’t catch a break

Excited to launch the second conference by The Netherlands Cancer Institute and Weizmann Institute on the latest developments in cancer research. Great speaker lineup and exciting data!

Wonderful Peeperlab retreat with mix of science and leisure: SWOTs, brainstorming, playing pool, canoeing and quality time together. Thanks to the team for organizing!

The research group headed by Daniel Peeper at The Netherlands Cancer Institute & Oncode Institute can get started on their research into a strategy to help future cancer patients benefit more from immunotherapy. Thanks to KWFKankerbestrijding! In focus: TWEAK-Fn14 signaling in tumor cells.

When your PI shows up for 5 minutes in the lab to provide experimental advices.

We’re hiring! 🔬3 exciting positions open for talented #postdocs interested in #ImmunotherapyResistance in #cancer. The Daniel Peeper lab is at the comprehensive The Netherlands Cancer Institute, using advanced techniques to improve #Immunotherapy. Join us: nki.nl/research/resea… #PostdocJobs #Immunology

Congrats to my postdoc Johanna Veldman for obtaining a prestigious NWO Funding Veni fellowship to improve cancer immunotherapy!

Back home full of ideas, and grateful again for being part of a great group of #melanoma scientists, which are not only fabulous researchers, but great fiends as well! Now, looking forward to the 15th European Melanoma Workshop!

Congratulations to Piet Borst, 2023 #LaskerAward winner! – “for an exceptional 50-year career of scientific discovery, mentorship, and leadership”. ow.ly/cuFl50PNTMJ #Lasker2023 #LaskerLaureate #mtDNA #mitochondria #trypanosomes

Congratulations to my student David Vredevoogd for receiving his PhD degree cum laude (with honors)! David, your thesis defense was as excellent as your scientific achievements. Best of luck in your future career!

Congrats to the 4 lead investigators Chun-Pu, Pierre, Astrid and Georgi from my lab The Netherlands Cancer Institute Oncode Institute + collaborators, reporting today in Cancer Cell several genes whose inactivation generates fitter immune T cells for enhanced tumor killing. cell.com/cancer-cell/fu…

Excited to share that Flindr Therapeutics (previously Immagene) today announced a €20 million Series A financing. Gratifying to witness a discovery from my lab translate into the development of a novel anticancer drug. Congrats to Maarten and his team on this major milestone!

Just returned from our lab retreat, this time in Malmedy. Nice mix of science and leisure with bubble football, pubquiz, BBQ and quality time together. This is a special group of people, happy to be part of it!

Happy to share a Nature Reviews Cancer / Nature Rev Immunol poster by Daniela Thommen & myself, showing new therapeutic approaches that are combined with PD1 blockade for synergistic clinical benefit, using mechanistic understanding of cancer–immune interactions rdcu.be/dPp2z